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Edited by Beat ImhofAbstract Majority of cancer cells upregulate co-inhibitory mol-
ecule B7-H1 which confers resistance to anti-tumor immunity,
allowing cancers to escape from host immune surveillance. We
addressed the molecular mechanism underlying the regulation
of cancer-associated B7-H1 expression in response to inter-
feron-c (IFN-c). Using promoter constructs in luciferase assay,
the region between 202 and 320 bp from the translational start
site is responsible for B7-H1 expression. Electrophoretic mobil-
ity shift assay, site-directed mutagenesis and knockdown exper-
iment using siRNA revealed that interferon regulatory factor-1
(IRF-1) is primarily responsible for the constitutive B7-H1
expression as well as for the IFN-c-mediated B7-H1 upregula-
tion in a human lung cancer cell line A549. Additionally,
AG490, a Janus activated kinase/signal transducer and activator
of transcription inhibitor, greatly abolished the responsiveness of
A549 cells to IFN-c by reducing the IRF-1 transcription. Our
ﬁndings support a critical role of IRF-1 in the regulation of con-
stitutive and IFN-c-induced expression of B7-H1 in cancer cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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B7-H1 (CD274, PD-L1), a member of B7 family, is a co-sig-
naling molecule that could be stimulatory or inhibitory for T
cell immunity through engagement of diﬀerent receptors ex-
pressed on T cells [1]. Small fraction of antigen-presenting
myeloid dendritic cells and Kupﬀer cells in liver express a
low level of endogenous B7-H1 on the surface. However, since
the B7-H1 expression in peripheral tissues is tightly regulatedAbbreviations: IRF-1, interferon regulatory factor-1; IFN-c, inter-
feron-c; JAK, Janus activated kinase; STAT, signal transducer and
activator of transcription
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doi:10.1016/j.febslet.2005.12.093in vivo, it is hard to detect B7-H1 expression in a variety of
normal tissues through immunohistochemical analysis [2,3].
Unlike normal cells of epithelial origin, human cancer cells,
including lung cancer, ovarian cancer, and melanoma, express
constitutively B7-H1 on the surface, and its expression is
greatly upregulated by interferon-c (IFN-c) [4].
IFN-c is a pro-inﬂammatory cytokine that is produced
mainly by activated type 1 CD4+ helper T cells (Th1), CD8+
cytotoxic T lymphocytes (CTLs), macrophages, and natural
killer (NK) cells, and regulates anti-viral and anti-tumor
immunity [5]. Collectively, in cancer microenvironment, can-
cer-speciﬁc or non-speciﬁc immune cells that are recruited into
cancer sites induce inﬂammation, a cellular process involving
the release of a wide variety of inﬂammatory mediators includ-
ing IFN-c [6], subsequently ensuing induction of various cellu-
lar proteins such as B7-H1 in cancer cells.
Overwhelming data indicate that cancer-associated B7-H1 in
murine cancer model facilitates apoptosis of cancer-reactive
CTLs or forms a molecular shield, resulting in suppression
of antitumor immunity [4,7]. In addition to the blockade of
cancer-associated B7-H1 using antagonistic B7-H1 antibody,
downregulation of B7-H1 expression by genetic or pharmaco-
logical methods may oﬀer alternative promising approaches
for cancer treatment. To manipulate B7-H1 expression genet-
ically or pharmacologically, it is necessary to understand
how its expression is regulated within cancer cells [8,9]. In a re-
cent publication, Loke et al. [10] reported that B7-H1 expres-
sion was enhanced on inﬂammatory macrophages by
classical activation by LPS and IFN-c in a STAT1/3-depen-
dent manner. However, it still remains unclear what molecular
mechanisms are involved in the constitutive and IFN-c-in-
duced B7-H1 expression in cancer cells.
In this study, we demonstrated that endogenously expressed
interferon regulatory factor-1 (IRF-1), a transcription factor, is
primarily responsible for the constitutive B7-H1 expression as
well as for the early induction of B7-H1 within 45 min after
IFN-c stimulation. Additionally, de novo synthesized IRF-1
through Janus activated kinase (JAK)/signal transducer and
activator of transcription (STAT) pathway is involved in the
late induction of B7-H1 expression in response to IFN-c.blished by Elsevier B.V. All rights reserved.
756 S.-J. Lee et al. / FEBS Letters 580 (2006) 755–7622. Materials and methods
2.1. Cell lines and reagents
A549 human lung carcinoma cell line, colorectal carcinoma
(Colo201 and WiDr), and HeLa cells were purchased from American
Type Culture Collection (Manassas, VA). SNU739 hepatocellular car-
cinoma cell line was purchased from Korean Cell Line Bank (Seoul,
Korea). Cells were grown in RPMI 1640 medium (GIBCO, NY) sup-
plemented with 10% heat inactivated fetal bovine serum (FBS). IFN-c
and AG490 were purchased from R&D Systems (Minneapolis, MN)
and Calbiochem (Ra Jolla, CA), respectively. PD98059, SB203580,
SP600125, and LY294002 were purchased from Biomol (Plymoth,
PA, USA). Rapamycin, PP1, Rottlerin, Staurosporine, and Genistein
were purchased from Sigma–Aldrich (St. Louis, MO, USA). pGL3 ba-
sic vector, pRL CMV vector and dual luciferase reporter assay kit were
purchased from Promega (Madison, WI). Restriction enzymes and
modiﬁed enzyme were purchased from Promega and TaKaRa (Seta,
Japan). Antibodies speciﬁc for IRF-1 and IRF-2 were purchased from
Cell Signaling Technology (Beverly, MA). [c-32P]-ATP and poly(dI-
dC)2 were obtained from Amersham Biosciences (Piscataway, NJ).
PE-conjugated streptavidin was obtained from Jackson ImmunoRe-
search (West Grove, PA). Anti-human B7-H1 (5H1) was generated
in our laboratory, and was described previously [11,12].
2.2. Flow cytometric analysis
Cells were stained with biotin-conjugated anti-human B7-H1 (5H1),
detected with PE-conjugated streptavidin, and analyzed using ﬂow
cytometry and CellQuestPro software (BD science, Franklin Lakes,
NJ). Cells were washed between the reactions in FACS buﬀer (1%
FCS and 0.1% NaN3 in PBS). B7-H1 expression on the surface was
represented as mean ﬂuorescence intensity (MFI).
2.3. Western blot
Whole cell extracts were prepared in the lysis buﬀer as described pre-
viously [13]. Protein extracts were subject to SDS–PAGE (10% gel),
transferred to nitrocellulose membranes (Schleicher & Schuell, NH),
and probed with antibodies. The respective bands were detected with
HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology Inc.,
CA). The amount of chemiluminescence was measured by LAS-3000
SYSTEM (Fuji Photo Film, Japan).
2.4. Preparation of promoter constructs
Human genomic DNA was isolated from human embryonic kidney-
293 (HEK-293) cell line using a DNeasy Tissue Kit (Qiagen, GmhH,
Germany). The 3-kb of 5 0-ﬂanking promoter region was ampliﬁed
from genomic DNA by PCR using upstream primer, 5 0-TGA CTC
GAG ACA CAT ATA GGA TGT GAG-3 0; downstream primer, 5 0-
TCT CTC GAG CCC AAA GAA AGG GTG TAG-30; The ampliﬁed
3036 bp fragment was cloned into TA-vector (pTA-3036) (Promega,
WI). The luciferase constructs were generated by digesting pTA-3036
DNA with appropriate restriction enzymes mapped on promoter re-
gion and by subcloning into pGL3 basic (Promega). Restriction en-
zymes used for generation of promoter constructs were as follows;
BamHI/XhoI (pH1-2405), SspI/BglII (pH1-1101), DraI/BglII (pH1-
633), HindIII/HindIII (pH1-202), and PvuII/HindIII (pH1-88). Excep-
tionally, pH1-457 and pH1-320 plasmids were created by PCR cloning
using speciﬁc forward primers (pH1-457: 5 0-ACG CCG AGC TCATable 1
Sequence of sense oligonucleotides used in site-directed mutagenesis and EM
Oligonucleotides Sequence (50 ﬁ 3 0)
IRF-1a
Wild-type ACT GGA CTG ACA TGT TT
Mutant ACT GGA CTG ACA TGT gT
IRF-1b
Wild-type CTA GAT ACC TAA ACT GA
Mutant CTA GAT ACC TAA gCT tA
Mutated bases are underlined [16,17]. Locations are relative to the ﬁrst tranTAA AGG TTA AGG-3 0, 457 bp; pH1-320: 5 0-ATC TTC GGA
GCT CTT CCC GGT G-3 0, 320 bp), and the downstream primer used
for PCR of 3036 bp fragment. The B7-H1 promoter sequence was ana-
lyzed for transcription factor binding sites within the promoter region
using a sequence motif search program of GenomeNet (http://motif.
genome.jp).
2.5. Transient transfection and luciferase assay
Luciferase assay was performed using Dual Luciferase Reporter As-
say System (Promega) according to the manufacturer’s instruction.
Luciferase assays were carried out using Wallac 1420 multilabeling
counter (Perkin–Elmer, CT). All ﬁreﬂy luciferase values were normal-
ized to Renilla luciferase in order to compare the transfection eﬃcien-
cies. Results were represented as means ± S.D. of a representative
experiment performed in triplicate.
2.6. Site-directed mutagenesis
Mutagenesis of IRF-1 in B7-H1 promoter region was generated
using a Quick Change site-directed mutagenesis system (Stratagene,
CA). The mutated primers used are listed in Table 1. PCR was per-
formed using two antiparallel primers with the required nucleotide
substitutions and the PCR product was used to transform XL1-Blue
supercompetent Escherichia coli cells (Stratagene). The sequences of
the mutation constructs were conﬁrmed by bi-directional DNA
sequencing.
2.7. EMSA analysis
Sense and antisense oligonucleotides encompassing the IRF-1 bind-
ing site in B7-H1 promoter were synthesized (Table 1). Electrophoretic
mobility-shift assay (EMSA) probes were made by annealing the oligo-
nucleotides and end-labeling the resulting double-stranded oligonucle-
otides using T4 polynucleotide kinase and [c-32P]-ATP. EMSA
analysis was performed using the Gel Shift Assay System (Promega)
with A549 nuclear extracts, prepared as previously described [14,15].
For supershift assays, protein extracts were preincubated with 2 lg
of anti-IRF-1, anti-IRF-2, and mouse IgG antibody for 4 h at 4 C
prior to binding reaction, and then subject to EMSA assay. The resul-
tant protein/DNA complexes were electrophoretically resolved on 5%
polyacrylamide gels in 0.5 · TBE buﬀer for 3 h at 120 V, and analyzed
by autoradiography. The relative band intensity was analyzed using
Image Acquisition and Analysis Program (UVP, Cambridge, UK).
2.8. RT-PCR
Total RNAs were isolated using Trizol reagent (Invitrogen, CA),
according to the manufacturer’s instructions. cDNA was generated
using ImProm-II Reverse Transcription System (Promega), which
was then ampliﬁed by PCR using speciﬁc primers for B7-H1 (forward,
5 0-GAC CTG AAG GTT CAG CAT AG-30; reverse, 5 0-GTA TCT
TGG ATG CCA CAT TT-3 0, 613 bp), IRF-1 (forward, 5 0-GTA
AGG AGG AGC CAG AAA TTG ACA GC-3 0; reverse, 5 0-CTA
CGG TGC ACA GGG AAT GGC CTG-30, 157 bp), and IFN-cR
(forward, 5 0-AGT ACC AGA TCA TGC CAC AGG TCC-3 0; reverse,
5 0-ATC GCT AAC TGG CAC TGA ATC TCG-3 0, 465 bp). The var-
ious inhibitors were used at working concentration such as AG490
(50 lM), PD98059 (50 lM), SP600125 (25 lM), SB203580 (25 lM),
LY294002 (25 lM) Rapamycin (6 nM), PP1 (2 lg/ml), Rottlerin
(10 lM), Staurosporine (0.1 lM) and Genistein (10 lM).SAs
Location
C ACT TTC TGT TTC 291 to 262
a ACc TTC TGT TTC
A AGC TTC CGC CGA 222 to 199
c AGC TTC CGC CGA
slation start site.
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Sense and antisense strands of small interfering RNA (siRNA) oli-
gonucleotides directed against IRF-1 mRNA were synthesized as a
duplex format (sense, 5 0-CCAAGAACCAGAGAAAAGAdTdT-3 0;
antisense, 5 0-UCUUUUCUCUGGUUCUUGGdTdT-3 0) [16,17].
A549 cells were plated at a density of 6 · 105 cells onto 6-well plate.
After 24 h, the cells were transfected with various concentrations of
IRF-1 siRNA or control siRNA using Lipofectamine 2000 (Invitro-
gen, CA) according to the manufacturer’s protocol.
2.10. Statistical analysis
Student’s t test was performed wherever applicable. Mean ± S.D. is
shown unless otherwise stated.Fig. 1. Eﬀect of IFN-c on the expression of B7-H1. (A) Total RNAs
were isolated from various human cancer cell lines grown in the
presence or absence of 100 U/ml IFN-c for 24 h and analyzed for the
relative levels of mRNA of B7-H1, IFN-c receptor (IFN-cR) or b-
actin by RT-PCR. (B) Human cancer cell lines treated as in Fig. 1A
were stained with anti-B7-H1 (thin line) and control antibody
(shaded area) and analyzed by ﬂow cytometry. (C) A549 cells were
stimulated with the indicated concentrations of IFN-c for 24 h. Total
RNAs were isolated from the cells and analyzed for B7-H1 mRNA
expression by RT-PCR. (D) The IFN-c-stimulated A549 cells were
stained with biotin-conjugated anti-B7-H1 (5H1) antibody, detected
with PE-conjugated streptavidin, and analyzed by ﬂow cytometry.
A549 cells were stimulated with 100 U/ml IFN-c for the indicated
times (0–48 h). Time-course eﬀect of IFN-c on the expression of B7-
H1 mRNA (E) or protein (F) in A549 cells was analyzed by RT-PCR
and ﬂow cytometry, respectively, as in C and D. All B7-H1
expressions on the cell surface are represented as a MFI in B, D,
and F.3. Results
3.1. B7-H1 is upregulated in A549 cells in response to IFN-c
RT-PCR analyses showed detectable expressions of consti-
tutive B7-H1 mRNA in most cancer cells tested, including
Colo201, WiDr, HeLa, and A549 cells. Exceptionally,
SNU739, a hepatoma cell line, expressed higher level of endog-
enous B7-H1 mRNA. Treatment of the various cancer cells
with 100 U/ml IFN-c for 24 h resulted in the induction of high
levels of B7-H1 mRNA expression (Fig. 1A). This ﬁnding was
consistent with protein expression as evidenced by FACS anal-
ysis (Fig. 1B). We also observed the upregulated B7-H1 expres-
sion in other cancer cell lines such as lung cancer cells (A427
and Calu-3), hepatoma (HepG2 and SNU449), and colon can-
cer cells (LS513) (Fig. S1). We found that the constitutive
expression of B7-H1 protein was more likely prominent than
B7-H1 mRNA expression in cancer cells. The ﬁnding that
the same treatment did not seem to aﬀect the expression of
the IFN-c receptor (IFN-c R) in any of the cancer cells tested
suggest that B7-H1 upregulation in response to IFN-c does not
occur by modulation of its receptor. Given the similarity of re-
sponses in the diﬀerent cancer cell lines, A549 was used in this
study. To determine the concentration of IFN-c revealing a
maximum expression of B7-H1, we treated A549 cells with var-
ious concentrations of IFN-c for 24 h. B7-H1 mRNA
(Fig. 1C) and protein (Fig. 1D) was maximally increased at
100–200 U/ml IFN-c. As shown in Fig. 1E and F, B7-H1
mRNA was slightly increased after 1 h of IFN-c treatment
and was further increased in a time-dependent manner thereaf-
ter. The maximal induction of B7-H1 mRNA and protein oc-
curred at 9–12 and 24 h, respectively. From the experiment to
demonstrate a stability of IFN-c-induced B7-H1 after with-
drawal of INF-c at 24 h of culture, we found that B7-H1
expression was decreased time-dependently at a similar rate
to that under IFN-c stimulation (Fig. S2).
3.2. Cloning and characterization of the B7-H1 promoter
A3.0-kb fragment of the B7-H1 promoter was ampliﬁed from
human genomic DNA by PCR and was cloned into a luciferase
reporter plasmid, pGL3 basic vector. The luciferase activity of
pH1-2405 was induced 3.0 (±0.6)-fold higher following IFN-c
treatment compared to that of untreated control. Reporter con-
structs containing promoter regions covering from nt 2405 to
nt 320 remained highly inducible in response to IFN-c
(Fig. 2A). There was a dramatic loss of promoter activity in
pH1-202 and pH1-88.While these constructs showed greatly re-
duced luciferase activity, they still displayed B7-H1 promoter
activity compared to pGL vector (Fig. 2, inset). Speciﬁcally,
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Fig. 2. Delineation of human B7-H1 promoter region. (A) Promoter constructs and restriction enzyme map of human B7-H1 promoter region. A549
cells were transiently cotransfected with various promoter constructs and empty luciferase vector pRL CMV for 36 h to compare transfection
eﬃciencies. The cells were left untreated or treated with 100 U/ml IFN-c for the last 9 h. Relative luciferase activity was determined as described
under Section 2. Results are represented as means ± S.D. of a representative experiment performed in triplicate. B, BamHI; Bg, BglII; D, DraI; Hc,
HincII; H,HindIII; P, PvuII; Sc, SacI; Ss, SspI; X, XhoI. (B) Nucleotide sequence of the promoter region of human B7-H1 gene. The 350-bp sequence
of the 5 0-ﬂanking region of B7-H1 is shown. The translation start site is indicated by +1. The arrow indicates the transcription start site. Underlined
sequences are possible transcription factor binding sites, as predicted by GenomeNet.
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erase activity is signiﬁcantly lower than that of pH1-320. These
results suggest that the promoter region between nt320 and nt
202 is more likely responsible for the basal or IFN-c-induced
B7-H1 promoter activity in A549 cells. A sequence motif search
of GenomeNet further identiﬁed transcription factor binding
sites in that region, including two IRF-1 sites (IRF-1a, -1b)
(Fig. 2B).
3.3. IRF-1 binds to the putative binding sites in B7-H1 promoter
To test the binding of IRF-1 to B7-H1 promoter region, we
performed EMSA analyses. As shown in Fig. 3A, IFN-c in-
creased the protein complex formation between IRF-1 and
the DNA probes. The formation of detectable complex was
competed out with 50-fold excess of unlabeled cold probe
(Fig. 3A). This result provides evidence that IRF-1 is induced
by IFN-c and binds to a speciﬁc site in the B7-H1 promoter.
Additionally, signal generated by the IRF-1–DNA complex
was supershifted in the presence of anti-IRF-1, not anti-IRF-
2, antibody, strongly indicating that the nuclear protein com-
plex that binds to the putative IRF-1 binding sequence in
B7-H1 promoter region contains IRF-1 protein. Furthermore,a time course analysis showed that maximum binding activity
of IRF-1 to B7-H1 promoter appeared in two phases; the ﬁrst
peak of binding activity within 5 min and the second peak at
7 h after IFN-c stimulation (Fig. 3B).
3.4. IRF-1 is prerequisite to constitutive and IFN-c-induced
B7-H1 transcription
In order to examine the eﬀect of IRF-1 on B7-H1 transcrip-
tion, we mutagenized the predicted transcription factor bind-
ing sites, IRF-1a and IRF-1b, in the pH1-320 promoter
construct. Luciferase assay using those mutants revealed that
mutation at the IRF-1a and -1b binding sites resulted in a
great reduction of constitutive- as well as IFN-c-induced B7-
H1 promoter activity by 80–90% (Fig. 4A), implying the
importance of these cis-acting elements and their involvement
in B7-H1 promoter activation. This notion was further
supported by the ﬁnding that IRF-1 siRNA signiﬁcantly
decreased the IFN-c-mediated IRF-1 expression and
subsequently suppressed IFN-c-induced B7-H1 mRNA and
protein expression by about 80% and 60%, respectively
(Fig. 4B). Additionally, IRF-1 siRNA greatly diminished B7-
H1 promoter activity in response to IFN-c in luciferase assay.
Fig. 3. EMSA of putative IRF-1 binding sites. (A) EMSA was
performed with nuclear extract obtained from A549 cells left untreated
or treated with 100 U/ml IFN-c for 9 h, indicated 32P labeled probes,
and indicated antibodies. The competition assay was performed with
50-fold excess of unlabeled cold probes. (B) Similar EMSA was
performed using nuclear extracts obtained from A549 cells stimulated
with 100 U/ml IFN-c for the indicated times. The relative band
intensity was analyzed by densitometry. Results shown are represen-
tative of at least three independent experiments.
Fig. 4. Contribution of IRF-1 to B7-H1 transcription. (A) A549 cells
were transfected for 36 h with promoter construct (pH1-320) contain-
ing mutation at IRF-1 binding sites; wild-type pH1-320 (wt-H1), IRF-
1a mutant (mut-IRF-1a), IRF-1b mutant (mut-IRF-1b). The cells
were left untreated or treated with 100 U/ml IFN-c for the last 9 h. The
cells were then lysed and assayed for relative luciferase activity under
Section 2. (B) A549 cells were transfected for 36 h with 100 nM of
control siRNA or various concentrations (50–200 nM) of IRF-1
siRNA and then stimulated with 100 U/ml IFN-c for the last 9 h (for
mRNA) and 24 h (for protein). B7-H1 mRNA and protein expression
was analyzed using RT-PCR and ﬂow cytometry, respectively. (C)
A549 cells were cotransfected with control siRNA or various concen-
trations of IRF-1 siRNA and pH1-320 construct for 36 h, and then
stimulated with 100 U/ml IFN-c for the last 9 h. Promoter activity was
represented as a relative luciferase activity. Results shown are
representative of at least three independent experiments. (D) Trans-
fection of control or IRF-1 siRNA into SNU739 and HeLa cells and
the analysis of B7-H1 and IRF-1 expression were done as in B.
c
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of IRF-1, and subsequently declined the constitutive expres-
sion of B7-H1 mRNA and protein (Fig. 4B), and downregu-
lated basal B7-H1 promoter activity in luciferase assay
(Fig. 4C). In line with this observation, we found that IRF-1
siRNA largely reduced the constitutive B7-H1 expression in
SNU739 that expresses high level of basal B7-H1 and greatly
diminished the IFN-c-induced B7-H1 expression in SNU739
and HeLa cells (Fig. 4D). Collectively, the data suggest that
IRF-1 plays a key role in constitutive B7-H1 expression and
in IFN-c-induced B7-H1 transcription in A549 cells. This
Fig. 5. Eﬀect of various signaling inhibitors on IFN-c-induced B7-H1
expression. (A) A549 cells were pretreated for 1 h with the indicated
inhibitors and then stimulated with 100 U/ml IFN-c in the presence or
absence of the same inhibitor for an additional 9 h. Total RNAs were
prepared and analyzed by RT-PCR for B7-H1 or b-actin. N, no
treatment; AG, AG490 (JAKII inhibitor); PD, PD98059 (ERK
inhibitor); SP, SP600125 (JNK inhibitor); SB, SB203580 (p38 inhib-
itor); LY, LY294002 (PI3K inhibitor); Ra, rapamycin (mTOR/p70S6K
inhibitor). (B) The same experiment as in Fig. 6A except for PP, PP1
(Src kinase inhibitor); RO, rottlerin (PKC inhibitor); ST, staurosporin
(PKC inhibitor); Ge, genistein (protein kinase inhibitor).
Fig. 6. The eﬀect of JAK/STAT pathway on B7-H1 expression. (A)
A549 cell were pretreated with various concentration of the JAKII
inhibitor AG490 for 1 h before stimulation with 100 U/ml IFN-c, and
then incubated in the presence or absence of AG490 for an additional 9
and 24 h, and then B7-H1 mRNA and protein expression were
analyzed. (B) A549 cells were transfected with promoter construct
pH1-320 and pretreated with 50 lM of AG490 for 1 h before 9 h-IFN-
c stimulation. Relative luciferase activity was determined. Results
shown are representative of at least three independent experiments.
760 S.-J. Lee et al. / FEBS Letters 580 (2006) 755–762notion was the case with primary normal cells including hu-
man dermal ﬁbroblasts and adipose stem cells (Fig. S2).
3.5. JAK/STAT pathway is responsible for regulation of IFN-c-
induced B7-H1 expression
It has been reported that IFN-c activates various intracellu-
lar signaling proteins such as JAK/STAT, PI3K, MTOR/p70-
S6K, ERK, JNK, p38, and protein kinases C (PKCs) [18]. We
sought to examine whether inhibition of these signaling pro-
teins aﬀects IFN-c-mediated B7-H1 expression in A549 cells.
We found that treatment with AG490 (an inhibitor of JAK/
STAT) greatly reduced the transcription of B7-H1 in the pres-
ence or absence of IFN-c compared to other inhibitors for sig-
naling proteins (Fig. 5A and B). Interestingly, there was a
detectable upregulation of B7-H1 transcription in A549 cells
treated with rottlerin and genistein (Fig. 5B). Taken together,
JAK/STAT pathway may be predominantly responsible for
the IFN-c-mediated B7-H1 transcription. This postulate was
further supported by the ﬁnding that pretreatment with
AG490 strongly reduced both basal expression and IFN-c-
induced upregulation of B7-H1 mRNA and protein in
dose-dependent mode (Fig. 6A). This was the case with
IRF-1 transcription in the presence of AG490 (Fig. 6A). In
consistent with this ﬁnding, basal and IFN-c-induced B7-H1
promoter activity was substantially diminished in the presence
of AG490 (Fig. 6B), an observation suggesting that JAK/
STAT pathway may be a key signaling pathway involved in
basal expression and IFN-c-induced upregulation of B7-H1
in A549 cancer cells.4. Discussion
IRF-1, a member of IRF family of 10 mammalian transcrip-
tion factors (IRF-1-10), reveals a great functional diversity in
the regulation of cellular response in host defense [19]. IRF-1
mRNA is expressed in a variety of cell types, and its expression
is dramatically upregulated upon viral infection or IFN stimu-
lation [20]. In this study, we demonstrated that IRF-1 is acritical transcription factor for both constitutive and IFN-c-in-
duced B7-H1 expression. This result was evidenced by the
observations from a site-directed mutagenesis study, in which
mutations of the IRF-1 binding site in B7-H1 promoter greatly
diminished the basal transcription of B7-H1 in A549 cells that
were unstimulated with IFN-c. Additionally, those mutations
appeared to completely abolish the responsiveness of A549
cells to IFN-c. In support of this ﬁnding, knockdown of
IRF-1 using siRNA greatly decreased both the constitutive
and IFN-c-induced transcription and translation of B7-H1 in
A549 cells. The data provide evidence that IRF-1 serves as
an essential transcription factor involved not only in the con-
stitutive but also in IFN-c-induced B7-H1 expression.
B7-H1 transcription and translation was induced as early as
1 h post-IFN-c stimulation. This early induction of B7-H1
expression may be largely mediated by the basally expressed
IRF-1, as demonstrated by the ﬁnding that cytoplasmic IRF-
1 was signiﬁcantly mobilized into a nucleus and to bind B7-
H1 promoter region as early as 5 min after IFN-c stimulation,
a time period during which IFN-c stimulation is probably not
suﬃcient to de novo synthesize IRF-1 through JAK/STAT
pathway [21,22]. In addition, the late IFN-c-mediated B7-H1
upregulation at 12–24 h after IFN-c stimulation may occur
through de novo synthesized IRF-1, which shows a maximal
binding activity to B7-H1 promoter at 7 h following IFN-c
stimulation. Based on the result of IRF-1 and B7-H1 transcrip-
tion in the presence of AG490, JAK/STAT can be demon-
strated as key signaling molecules responsible for basal and
IFN-c-induced transcription of IRF-1 and B7-H1. From the
S.-J. Lee et al. / FEBS Letters 580 (2006) 755–762 761data on PKC inhibitor-induced upregulation of B7-H1 in the
absence of IFN-c, however, we cannot exclude the possibility
that other signaling pathway such as PKC might be involved
in basal expression of B7-H1.
From the promoter activity assay using various promoter
constructs, we found that promoter region from nt 457
and nt 2405 was implicated in an inhibition of promoter
activity in response to IFN-c compared to pH1-457 and
pH1-320 which showed maximal B7-H1 promoter activity.
This observation suggests that promoter region upstream to
nt 457 may contain binding site(s) for some inhibitory tran-
scription factor(s). It remains to be illustrated in the future
study. NF-jB is a well-known transcription factor involved
in many immunological events, such as inﬂammatory cyto-
kine production, TCR-mediated T cell activation, and regula-
tion of co-signaling molecules [12,23,24]. Interestingly,
although B7-H1 promoter contains an NF-jB binding site
at nt 182, NF-jB is unlikely to play a key role in the tran-
scription of B7-H1 in A549 lung cancer cells, as evidenced by
the luciferase assay in which promoter construct containing
NF-jB binding site greatly abolished the responsiveness of
A549 cells to IFN-c. Recently, a publication suggested that
NF-jB is essential for IFN-c-induced B7-H1 upregulation
in normal dermal ﬁbroblast, and PI3K is involved in this
upregulation [25]. We suppose that this discrepancy in terms
of transcription factor and signal pathway involving B7-H1
transcription may result from the diﬀerent cell types, cancer
and normal cells, in which IFN-c may trigger activation of
diﬀerent signaling proteins, whose activation may diﬀerently
involve B7-H1 expression.
It is conceivable that tumor cells that are exposed to IFN-c in
the cancer microenvironment, which can exert harsh conditions
for cancer cells, can escape immune surveillance by suppressing
cancer-speciﬁc CTLs through upregulation of a co-inhibitory
molecule B7-H1 on the surface. Therefore, one should be
cautious to the use of IFN-c as a therapeutic agent for cancer
treatment. Thus understanding the molecular mechanism of
regulation of B7-H1 expression in cancers may shed a light
on a development of alternative strategies for cancer treatment
including cytokines or pharmaceutical compounds downregu-
lating the cancer-associated B7-H1 expression.
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